CTOs on the Move

Carisma Therapeutics

www.carmatherapeutics.com

 
Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Carisma Therapeutics raised $53M on 06/27/2018

Similar Companies

Precision IBD

Precision IBD, Inc. is a biopharmaceutical company focused on the discovery an development of a broad portfolio of precision therapeutics and companion diagnostics for inflammatory bowel disease.

IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

AgriThority

AgriThority® is the first independent data-through-delivery product and market development company in the agriculture industry. Instead of delivering a “data dump” and walking away, AgriThority® assimilates and summarizes data to ensure you get the consistency and continuity your project demands. Producers benefit, too. AgriThority® has unmatched strength in the development of best management practices (BMPs) in animal health, agronomic and horticultural crop production, and in the development of product use within those BMPs. AgriThority® further builds trust and credibility for products and innovations by providing and delivering training and educational programs for company sales and field development organizations, technical influencers, channel partners and producers.

Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.

Xcellerex

Xcellerex is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.